Volume 58, Issue 2, (February 2013)

Slides:



Advertisements
Similar presentations
Cancer Metabolism Cell Volume 148, Issue 3, (February 2012) DOI: /j.cell Copyright © 2012 Terms and Conditions Terms and Conditions.
Advertisements

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Global gene repression in hepatocellular carcinoma and fetal liver, and suppression of dudulin-2 mRNA as a possible marker for the cirrhosis-to-tumor transition.
Volume 63, Issue 1, Pages (July 2015)
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Volume 46, Issue 3, Pages (March 2007)
Volume 59, Issue 1, Pages (July 2013)
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)
MELD: the holy grail of organ allocation?
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Reply to: “Serum HBV pgRNA as a clinical marker for cccDNA activity”
Volume 58, Issue 2, (February 2013)
Hepatic CD141+IFNλ+ DC subset: One against all?
Volume 51, Issue 6, Pages (December 2009)
Reactive oxygen species in the normal and acutely injured liver
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 44, Issue 2, Pages (February 2006)
Immigration and viral hepatitis
Volume 66, Issue 1, Pages 1-4 (January 2017)
The evidence supports a viral aetiology for primary biliary cirrhosis
Living donor liver transplantation: is the hype over?
Mesenchymal stromal cell therapy for liver diseases
Volume 44, Issue 6, Pages (June 2006)
Volume 64, Issue 5, Pages (May 2016)
The place of downstaging for hepatocellular carcinoma
Hepatitis C core protein – The “core” of immune deception?
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Aloysious D. Aravinthan, Graeme J.M. Alexander  Journal of Hepatology 
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 45, Issue 4, Pages (October 2006)
Volume 62, Issue 3, Pages (March 2015)
Volume 59, Issue 3, Pages (September 2013)
Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore 
EASL Clinical Practice Guidelines: Wilson’s disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Volume 61, Issue 1, Pages S45-S57 (November 2014)
HCMV jogs the ‘memory’ of NK cells in HBV
Volume 57, Issue 5, Pages (November 2012)
Volume 50, Issue 4, Pages (April 2009)
Non-invasive diagnosis and biomarkers in alcohol-related liver disease
Paul C. Adams, James C. Barton  Journal of Hepatology 
Erratum The American Journal of Human Genetics
Volume 56, Issue 6, Pages (June 2012)
Chetana Lim, Chady Salloum, Daniel Azoulay
Immigration and viral hepatitis
The potential of induced pluripotent stem cell derived hepatocytes
Clinical Practice Guidelines of the European Association for the study of the Liver – Advancing methodology but preserving practicability  Markus Cornberg,
Global burden of alcoholic liver diseases
The impact of intestinal microflora on serum bilirubin levels
Volume 63, Issue 1, Pages (July 2015)
Familial amyloidosis: Great progress for an orphan disease
The use of hemospray in portal hypertensive bleeding; a case series
Volume 62, Issue 3, Pages (March 2015)
Volume 65, Issue 4, Pages (October 2016)
Liver transplantation in children
Ana Lleo, M. Eric Gershwin, Alberto Mantovani, Pietro Invernizzi 
Reply to: “Flow cytometry makes all the difference”
Pathogenesis of cholestatic hepatitis C
Chimeric mouse model of hepatitis B virus infection
Corrigendum to “Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury” [J Hepatol 49 (2008) 88–98]  Angela Douglass,
Volume 50, Issue 1, Pages 4-6 (January 2009)
Genetics of hepatocellular carcinoma: The next generation
MELD: the holy grail of organ allocation?
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Presentation transcript:

Volume 58, Issue 2, (February 2013) Erratum to: “Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations” [J Hepatol 2011;55:838–845]  Xiaoli Chen, Shilpa Lingala, Shiva Khoobyari, Jan Nolta, Mark A. Zern, Jian Wu  Journal of Hepatology  Volume 58, Issue 2, (February 2013) DOI: 10.1016/j.jhep.2012.10.001 Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Flow cytometric analysis of hepatoma cells. (A) CD133+/ALDHhigh cells in hepatoma cell lines. (B) CD133+/EpCAM+ cells in hepatoma cell lines. CD133+/ALDHhigh and CD133−/ALDHlow or CD133+/EpCAM+ and CD133−/EpCAM− cells were separated by FACS after staining with APC-conjugated anti-CD133 antibody and an Adelfluor kit (A) or with APC-conjugated anti-CD133 and FITC-conjugated anti-EpCAM antibodies (B). Journal of Hepatology 2013 58, DOI: (10.1016/j.jhep.2012.10.001) Copyright © 2012 European Association for the Study of the Liver Terms and Conditions